<DOC>
	<DOCNO>NCT00716976</DOCNO>
	<brief_summary>RATIONALE : Sodium thiosulfate may reduce prevent hearing loss young patient receive cisplatin cancer . It yet know whether sodium thiosulfate effective additional treatment prevent hearing loss . PURPOSE : This randomized phase III trial study sodium thiosulfate see well work prevent hear loss young patient receive cisplatin newly diagnose germ cell tumor , hepatoblastoma , medulloblastoma , neuroblastoma , osteosarcoma , malignancy .</brief_summary>
	<brief_title>Sodium Thiosulfate Preventing Hearing Loss Young Patients Receiving Cisplatin Newly Diagnosed Germ Cell Tumor , Hepatoblastoma , Medulloblastoma , Neuroblastoma , Osteosarcoma , Other Malignancy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare efficacy sodium thiosulfate v observation prevent hearing loss young patient receive cisplatin treatment newly diagnose germ cell tumor , hepatoblastoma , medulloblastoma , neuroblastoma , osteosarcoma , malignancy . Secondary - To compare mean change hearing threshold key frequency patient . - To compare incidence cisplatin-related grade 3 4 nephrotoxicity grade 3 4 cytopenia patient . - To compare event-free survival overall survival patient . - To evaluate association two key gene mutation ( TPMT COMT ) development cisplatin-induced hearing loss patient . OUTLINE : This multicenter study . Patients stratify accord prior cranial radiation ( yes v ) , age ( &lt; 5 year vs ≥ 5 year ) duration cisplatin infusion ( &lt; 2 hour vs ≥ 2 hour ) . Patients randomize 1 2 arm . - Arm I ( sodium thiosulfate ) : Patients receive sodium thiosulfate IV 15 minute begin 6 hour completion cisplatin infusion . Treatment sodium thiosulfate continue completion cisplatin therapy . - Arm II ( observation ) : Patients receive sodium thiosulfate . Patients undergo audiological assessment baseline , prior course cisplatin , 4 week 1 year last course cisplatin cancer treatment . Some patient may undergo saliva collection DNA study . After completion study , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Hepatoblastoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Sodium thiosulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose ( previously untreated currently receive cancer treatment diagnosis make patient eligible study ) germ cell tumor , hepatoblastoma , medulloblastoma , neuroblastoma , osteosarcoma , malignancy Planning receive chemotherapy treatment regimen include cumulative cisplatin dose ≥ 200 mg/m² individual cisplatin dos infuse ≤ 6 hour Enrolled hear assessment clinical trial COGACCL05C1 Normal auditory result PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( patient &gt; 16 year age ) Lansky PS 50100 % ( patient ≤ 16 year age ) Serum sodium normal Absolute granulocyte count &gt; 1,000/mm³ Platelet count &gt; 100,000/mm³ Creatinine clearance radioisotope glomerular filtration rate ≥ 70mL/min OR serum creatinine 0.4 1.7 mg/dL , base age gender Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age AST ALT &lt; 2.5 time ULN age Not pregnant nursing Negative pregnancy test ( patient childbearing capacity ) Fertile patient must use effective contraception No known hypersensitivity sodium thiosulfate thiol agent ( e.g. , amifostine trihydrate , Nacetylcysteine , MESNA , captopril ) PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior platinumbased chemotherapy ( cisplatin carboplatin ) Other prior chemotherapy allow Prior cranial radiotherapy ( e.g. , treatment medulloblastoma ) allow provide normal hearing document completion radiotherapy enrollment administration cisplatin chemotherapy At least 6 month since prior hematopoietic stem cell transplantation . No evidence graftversushost disease No concurrent enrollment another COG clinical trial treatment cancer . Concurrent enrollment nonCOG clinical trial ( e.g. , Head start ) allow . Cranial irradiation completion systemic chemotherapy allow provide post endoftreatment audiometry complete prior begin irradiation . Concurrent radiotherapy extracranial site allow .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ototoxicity</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood extracranial germ cell tumor</keyword>
	<keyword>childhood extragonadal germ cell tumor</keyword>
	<keyword>childhood malignant testicular germ cell tumor</keyword>
	<keyword>childhood malignant ovarian germ cell tumor</keyword>
	<keyword>childhood teratoma</keyword>
	<keyword>childhood medulloblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>childhood hepatoblastoma</keyword>
	<keyword>stage I childhood liver cancer</keyword>
	<keyword>stage II childhood liver cancer</keyword>
	<keyword>stage III childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
</DOC>